Translational Development Acquisition Corp.
TDAC- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0001926599
No open-market purchases or sales by Translational Development Acquisition Corp. insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $154.1M in total; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −13 vs. previous quarter
- 35
- 13F valueReported value at the end of Q2 2026
- $154.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- $6.36M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.74K
- Shares sold short
- Change
- +751
- +37.8% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding TDAC, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TDAC at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Translational Development Acquisition Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 (view filing) | May 27 | 2 days | Hoffman Michael BChairman and CEO | PPurchaseClass A ordinary shares | +53.4K | $0.79 | +$42.2K | –53.4K after | Derivative |
Top 10 13F holders, Q2 2026
See all 35 holdersThe largest institutional positions in Translational Development Acquisition Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Linden Advisors LP | 1,150,000 | $12.3M | 0.06% | +550,000+91.7% | Added |
| Kryger Capital LLC | 1,141,050 | $12.2M | 0.70% | +1,141,050 | New |
| Magnetar Financial LLC | 1,000,000 | $10.7M | 0.10% | −300,000−23.1% | Reduced |
| CNH Partners LLC | 974,300 | $10.4M | 0.15% | −119,910−11.0% | Reduced |
| Wolverine Asset Management LLC | 944,878 | $10.1M | 0.13% | −306,478−24.5% | Reduced |
| Meteora Capital, LLC | 919,000 | $9.82M | 0.81% | +662,746+258.6% | Added |
| Highbridge Capital Management LLC | 861,837 | $9.21M | 0.31% | +823,198+2,130.5% | Added |
| LMR Partners LLP | 800,000 | $8.55M | 0.06% | 00.0% | Unchanged |
| Tenor Capital Management Co., L.P. | 635,399 | $6.79M | 0.10% | 00.0% | Unchanged |
| Alberta Investment Management Corp | 600,000 | $6.41M | 0.04% | 00.0% | Unchanged |
Holders of 5% or more of TDAC
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Translational Development Acquisition Corp..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Goldman Sachs Group Inc | 13G/A | 7.20%1.06M shares | +1.10 ppfrom 6.10% | May 13, 20262 filings | Aug 12, 2026 | SEC |
| Linden Capital L.P. | 13G/A | 6.70%1.15M shares | +1.20 ppfrom 5.50% | Jun 2, 20262 filings | Aug 14, 2026 | SEC |
| AQR Capital Management LLC | 13G/A | 6.38%1.10M shares | −2.23 ppfrom 8.61% | Feb 14, 20252 filings | May 14, 2025 | SEC |
| Meteora Capital, LLC | 13G | 6.27%919.0K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Magnetar Financial LLC | 13G/A | 5.18%1.00M shares | – | Nov 13, 20261 filing | Nov 13, 2026 | SEC |